

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 January 2023 (19.01.2023)



(10) International Publication Number
WO 2023/287352 A3

(51) International Patent Classification:

C07K 16/08 (2006.01) A61P 31/14 (2006.01)
A61K 39/42 (2006.01) G01N 33/53 (2006.01)

(21) International Application Number:

PCT/SG2022/050468

(22) International Filing Date:

06 July 2022 (06.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202107784Y 15 July 2021 (15.07.2021) SG

(71) Applicant: NATIONAL UNIVERSITY OF SINGAPORE [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG).

(72) Inventors: MACARY, Paul Anthony; c/o National University of Singapore, Life Sciences Institute, 21 Lower Kent Ridge Road, Singapore 119077 (SG). JHAJHARIA, Saket; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Microbiology & Immunology, 21 Lower Kent Ridge Road, Singapore 119077 (SG). LIM, Seng Gee; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Medicine, 21 Lower Kent Ridge Road, Singapore 119077 (SG). CHEN, Qingfeng; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Microbiology & Immunology, 21 Lower Kent Ridge Road, Singapore 119077 (SG). LAI, Fritz; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Medicine, 21 Lower Kent Ridge Road, Singapore 119077 (SG).

(74) Agent: DOWSING, Bruce John; Marks & Clerk Singapore LLP, Tanjong Pagar Post Office, P.O. Box 636, Singapore 910816 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: ANTI-HBV ANTIBODIES AND USES THEREOF




Figure 7I

(57) Abstract: The present invention relates to isolated and engineered human antibodies that specifically bind to at least one conformational (non-linear) epitope of HBsAg and neutralizes hepatitis B virus infection, method for producing the same, and uses thereof in treating human HBV infection.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

23 February 2023 (23.02.2023)